Amarantus BioScience Holdings, Inc. is a biopharmaceutical company, which engages in developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. It focuses on acquiring product and technology rights, raising capital, and performing research and development. The company was founded by Gerald E. Commissiong and John W. Commissiong on January 14, 2008 and is headquartered in New York, NY.